Brooks Allen (Orcid ID: 0000-0003-3773-3024)
Scott Peter (Orcid ID: 0000-0002-6505-0450)

An Updated Synthesis of N_1'-([^{11}C]Methyl)Naltrindole for Positron Emission Tomography Imaging of the Delta Opioid Receptor

Tanpreet Kaur, Allen F. Brooks, Brian G. Hockley, Jovany Torres, Bradford D. Henderson, Peter J. H. Scott,* Xia Shao*

Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, United States

Abstract



[^{11}C]MeNTI

A new method for the synthesis of the highly selective delta opioid receptor (DOR) antagonist radiotracer N_1'-([^{11}C]methyl)naltrindole ([^{11}C]MeNTI) is described. The original synthesis required hydrogentation of a benzyl protecting group after ^{11}C-labeling, which is challenging in modern radiochemistry laboratories that tend to be heavily automated and operate according to current Good Manufacturing Practice. To address this challenge we describe development of a novel MeNTI precursor bearing a methoxymethyl acetal (MOM) protecting group which is easily removed with HCl, and employ it in an updated synthesis of [^{11}C]MeNTI. The new synthesis is fully automated and validated for clinical use. The total synthesis time is 45 min and provides [^{11}C]MeNTI in good activity yield (49 ± 8 mCi), molar activity (3926 ± 326 Ci/mmol) and radiochemical purity (97 ± 2%).

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jlcr.3898

1. Introduction

Opioids exhibit their requisite pharmacological effects through binding to opioid receptors (OR) which are a group of G-protein-coupled receptors (GPCRs).[1] Distinct opioid receptors are described in the literature: μ opioid receptors (MOR), δ opioid receptors (DOR), κ opioid receptors (KOR) and opioid receptor-like 1 (ORL-1, also termed nociceptin opioid peptide (NOP) receptor).[2] Targeting ORs has a very crucial historical role in analgesia, with most historical opioids targeting MORs. However, while MOR agonists are effective analgesics, they also cause euphoric feelings that can lead to addiction. This issue has come to a head during the opioid epidemic that is plaguing the United States (overdoses involving opioids killed nearly 47,000 people in 2018[3]), leading to an urgent need for development of alternative non-addictive analgesics. With this in mind, opioid researchers are increasingly turning to the other ORs as alternatives to MORs.[4] For example, DORs also serve as a target of interest for pain management, as well as treatment of migraine and depression, but with less risk of addiction.[5,6] Key to the development of drugs for these other receptors is a thorough understanding of the entire opioid system[4] and, since the late 1970s/early 1980s, positron emission tomography (PET) imaging has played an important role in opioid research and contributed to our knowledge of opioid pharmacology (for recent reviews of OR imaging, see: [7,8,9,10]). In recent years, there has been a noticeable growth in opioid receptor imaging,[7] due to both the important role ORs play in pharmacology of many systems and disorders, and the opioid epidemic.

The PET Center at the University of Michigan has an extensive history in opioid PET imaging, and we currently use [^{11}C]carfentanil (MOR),[11,12] [^{11}C]LY2795050 (KOR)[13,14] and [^{11}C]NOP-1A (ORL-1/NOP)[15,16] in such studies. However, we have never conducted any DOR PET imaging. The DOR is expressed in the central nervous system (CNS) and the peripheral region. In the CNS, DORs are found in the cerebral cortex, caudate putamen and the nucleus accumbens.[6] Activation of DORs results in many physiological and behavioral effects including modulation of

antinociception, mood, sensory system, motor integration and cognitive functions.[6,17] In addition, DORs are also present in several immunocompetent cells, which suggests their pivotal role in regulating the immune system.[18] In order to have a complete opioid imaging toolbox available for our clinical collaborators, we were interested in expanding our imaging portfolio to include a radiotracer for DORs. Of the available DOR PET ligands, N_1'-([^{11}C]methyl)naltrindole ([^{11}C]MeNTI) is the most widely used to date.[19] Portoghese and co-workers found that MeNTI is a highly potent DOR antagonist (K_i = 20 pM) that exhibits >700-fold selectivity over MOR, and >3000 times over KOR.[20] It has been used in PET imaging studies for the localization and quantification of DORs in the human brain and heart,[21,22,23] as well as for imaging DORs expressed by primary tumors in certain cancer patients.[24] We therefore selected this agent to qualify for clinical use at our institution.

Upon review of existing radiosyntheses of [^{11}C]MeNTI, it became apparent that synthesis of the radiotracer is quite complex and this has perhaps limited widespread adoption of the imaging agent. The first radiosynthesis of [^{11}C]MeNTI was published by Lever *et al.* in 1995 and involved ^{11}C-methylation of 3-*O*-benzyl-naltrindole precursor with [^{11}C]MeI in DMF under basic conditions.[19] Final deprotection of the benzyl protecting group was accomplished under heterogenous catalytic conditions (10% Pd/C / H_2 or methanolic ammonium formate) to provide [^{11}C]MeNTI in 6% radiochemical yield (RCY) and in a molar activity of 76 GBq/μmol (Figure 1a). When considering technology transfer of this method to our laboratory, we reasoned reductive deprotection of the benzyl group would be particularly difficult with the automated synthesis modules that have become common place in light of current Good Manufacturing Practice (cGMP) regulations introduced since the original [^{11}C]MeNTI synthesis. While commercial solutions like the H-Cube have simplified hydrogenation reactions in a radiochemistry setting,[25] they are still not widely available. Consistent with our continuing efforts to simplify existing radiosyntheses for routine production of PET radiotracers,[12,26] herein we report a novel MeNTI precursor bearing a methoxymethyl acetal (MOM) protecting group, which can easily be removed with HCl (Figure

1b). We employ this method in an updated synthesis of [^{11}C]MeNTI that is fully automated and validated for clinical use.



Figure 1. Strategies for the synthesis of [^{11}C]MeNTI

2. Experimental

2.1 General Considerations

Full experimental details for syntheses and radiosyntheses, including copies of NMR spectra and radio-HPLC traces, are provided in the Supporting Information.

2.2 Synthesis of [^{11}C]MeNTI

[^{11}C]MeNTI was produced using a General Electric (GE) Tracerlab $FX_{C\text{-}Pro}$ automated radiochemistry synthesis module. [^{11}C]CO_2 was produced via $^{14}N(p,\alpha)^{11}C$ nuclear reaction using a GE PET Trace cyclotron (60 μA beam for 45 min) and converted by standard procedures[27] into carbon-11 labeled [^{11}C]CH_3OTf (~1 Ci). The precursor (MOM-protected NTI (**5**), 1 mg) was dissolved in DMF (100 μL) and TBA-OH (1.0 M in MeOH, 2.1 μL) was added to the reactor. [^{11}C]CH_3OTf was sparged (bubbled) through the reaction solution for 3 min at room temperature (rt) at a rate of 15 mL/min. 2M HCl (300 μL) was then added to remove the MOM group, and the reactor was heated at 80 °C for 5 min. After this time, the reaction was cooled to 50 °C and quenched with 2M NaOH (400 uL). The crude reaction mixture was purified using semi-preparative HPLC (column: Luna C18 250x10 mm-5μ, flow rate: 4 mL/min, mobile phase: 30% acetonitrile, 10 mM NH_4OAc, 0.2% AcOH). The product peak (t_R ~12 min) was collected into 50 mL of water and then loaded onto a C18 Sep-Pak (1 cc). The Sep-Pak was rinsed with water (10 mL) and [^{11}C]MeNTI was eluted with ethanol, USP (0.5 mL) and diluted with saline, USP (9.5 mL). The final product was filtered through a 0.22 μm sterile filter into a sterile dose vial and submitted for quality control testing. The overall synthesis time was 45 min from end-of bombardment (EOB).

2.3 Quality Control Testing

Quality control of [^{11}C]MeNTI was conducted according to the guidelines outlined in Chapter <823> of the U.S. Pharmacopeia and previously reported standard procedures.[27,28] HPLC analysis is described in Section 2.3.1. Results for three process verification batches using the new method

are summarized in Table 3. Doses met all acceptance criteria confirming their suitability for clinical use and validating the synthesis method for future production.

2.3.1 HPLC Analysis

Chemical and radiochemical purity of [^{11}C]MeNTI was analyzed using a Shimadzu LC2010 HPLC equipped with a Bioscan/Eckert and Ziegler radioactivity detector and an ultraviolet (UV) detector (Column: Luna C18 150x4.6 mm-5µ, flow rate: 2 mL/min, mobile phase: 40% MeCN, 10 mM NH_4OAc, 0.2% AcOH, pH 4.4, t_R ~5 min). Representative HPLC traces are provided in the Supporting Information.

3. Results and Discussion

We first synthesized naltrindole (NTI, **1**) and N_1'-methylnaltrindole (MeNTI, **2**) reference standards using a reported Fischer-indole synthesis.[29] The synthesis was carried out by condensation of naltrexone with the appropriate phenylhydrazine under mild acidic conditions in water, resulting in NTI (**1**) and MeNTI (**2**) in 98% and 73% yields, respectively (Scheme 1).



Scheme 1. Synthesis of NTI (1) and MeNTI (2) using Fischer Indole condensation

Initial work focused on [^{11}C]methylation of NTI (**1**) as it is well known in the literature that sterically crowded tertiary hydroxyl groups at the C-14 position of 4,5-α-epoxymorphinans are unreactive towards alkylating agents.[19] We therefore studied if ^{11}C-methylation of **1** could provide the desired product [^{11}C]MeNTI ([^{11}C]**2**) without protecting the phenol. However, attempts to methylate **1** with [^{11}C]MeOTf did not generate [^{11}C]**2** (Table 1, entries 1 and 2). Since we have

synthesized many ^{11}C-labeled PET imaging agents using loop chemistry, we attempted methylation of **1** in the loop at rt using 3-pentanone as the solvent but this was also unsuccessful (Table 1, entry 3). Loop chemistry employing DMF as the solvent was also attempted, and did generate [^{11}C]MeNTI but only in trace amounts (Table 1, entry 4).

Table 1: Initial attempts to synthesize [^{11}C]MeNTI



NTI (**1**) [^{11}C]MeNTI ([^{11}C]**2**) NTI-O[^{11}C]Me ([^{11}C]**3**)

Entry	Solvent[a]	Additive	RCY[b] for [^{11}C]**2** (%)	RCY[b] for [^{11}C]**3** (%)
1.	DMF, rt[c], 3 min	-	nd[d]	nd
2.	DMF, 80 °C, 3 min	-	nd	nd
3.	3-Pentanone, rt, Loop chemistry	-	Multiple peaks observed by RAD detector	nd
4.	DMF, rt, loop chemistry	-	<1.0	nd
5.	Ethanol, rt, 3 min	sat. NH_4Cl	nd	nd
6.	DMF, rt, 3 min	TBA-OH	nd	55

[a] Solvent (100 μL); [b] The identity of [^{11}C]**2** and [^{11}C]**3** was confirmed by radio-HPLC; [c] rt = room temperature; [d] nd = not detected.

Since NTI has both a phenolic group and a tertiary amine group, it is possible that it has zwitterionic characteristics that can affect methylation. To investigate this possibility, we thought inclusion of a protic additive (NH_4Cl, 40 μL, 0.05 M in ethanol) in the reaction mixture might promote the reaction but unfortunately this was also unsuccessful (Table 1, entry 5). To improve the RCY, we therefore considered addition of base to the reaction mixture. *Tetra*-butylammonium hydroxide (TBA-OH, 2.2 μL, 1.0 M in methanol) was included in the loop synthesis of [^{11}C]MeNTI but, unfortunately, HPLC analysis confirmed production of NTI-O[^{11}C]Me ([^{11}C]**3**)

as the major product instead due to preferential ^{11}C-methylation of the phenol (Table 1, entry 6). Consequently, to achieve the yield required for routine clinical production we moved away from unprotected precursor **1**, and instead focused upon developing a new protection strategy compatible with the zwitterionic character of NTI and amenable to cGMP compliant automation.



Scheme 2. Synthesis of acetate- and MOM-protected NTI analogs **4** and **5**

We initially explored protection of the phenol with an acetate group (Scheme 2). Starting from **1**, NTI-OAc (**4**) was obtained in 75% yield. However, attempts to ^{11}C-methylate **4** ([^{11}C]MeOTf , TBA-OH) revealed the acetate protecting group was unstable during the radiosynthesis and only NTI-O[^{11}C]Me ([^{11}C]**3**) was formed. To address this, we next decided to protect the phenol with a MOM group because of its stability to basic conditions (Scheme 2). Moreover, the MOM protecting group is easily removed under mild acidic conditions (2M HCl) making it more attractive than the benzyl group used in the original synthesis that requires either harsh forcing conditions (e.g. conc. HBr) or reduction methods for removal. We treated NTI (**1**) with MOM-Cl in the presence of K_2CO_3, which generated the desired precursor NTI-OMOM (**5**) in 55% yield. In exploratory radiochemistry, a mixture of NTI-OMOM (**5**) and TBA-OH in DMF was sparged with [^{11}C]MeOTf for 3 min at rt and provided the desired labeled intermediate [^{11}C]Me-NTI-OMOM as the major product (confirmed by co-elution with unlabeled Me-NTI-OMOM reference standard in HPLC analysis). Subsequent deprotection with 2M HCl at 80 ºC for 5 min. provided [^{11}C]MeNTI ([^{11}C]**2**) in 70% RCY, estimated by radio-HPLC (Table 2, entry 1). In an attempt to develop a greener approach for the synthesis, we also tried to employ a Class 3 solvent instead of

DMF.[30] Conducting the labeling in ethanol failed to provide product (Table 2, entry 2), while using DMSO gave product in lower (50%) RCY (Table 2, entry 3). Use of alternative bases (NaH) and ^{11}C-methylating agents ([^{11}C]MeI) was explored (Table 2, entries 4 and 5), but both of these changes resulted in lower RCYs and complex mixtures. Thus, the use of [^{11}C]MeOTf in DMF for 3 min. at rt proved to be the optimal conditions for the preparation of [^{11}C]MeNTI (Table 2, entry 1).

Table 2: Automation results for the synthesis on [^{11}C]MeNTI ([^{11}C]**2**)



Entry	Solvent	Base	Alkylating agent	RCY (%)
1.	DMF, rt[a]	TBA-OH[b]	[^{11}C]MeOTf	70
2.	Ethanol, rt	TBA-OH[b]	[^{11}C]MeOTf	nd[c]
3.	DMSO, rt	TBA-OH[b]	[^{11}C]MeOTf	50[d]
4.	DMF, rt	NaH[e]	[^{11}C]MeOTf	54
5.	DMF, rt	TBA-OH[b]	[^{11}C]MeI	45

[a] rt = room temperature; [b] TBA-OH (2.2 µL, 1.0 M in methanol), [c] nd = not detected (product was not formed), [d] n=2; [e] NaH (1.2 mg).

Lastly, we automated the optimal conditions and validated the process for clinical production. After synthesis and deprotection, [^{11}C]MeNTI was purified by semi-preparative HPLC (column: Luna C18, 5 micron, 250 x 4.6 mm; mobile phase: 30% acetonitrile, 10 mM NH_4OAc, 0.2% acetic acid; flow rate: 4 mL/min), and this chromatographic system gave good separation of [^{11}C]MeNTI (t_R = 12.5-14.5 min) from NTI produced from concomitant deprotection of residual MOM-protected precursor (t_R = 8-10 min). [^{11}C]MeNTI was reformulated using a C18 cartridge and the final dose was passed through a 0.22 µm Millex GV sterile filter (Millipore) into a sterile dose vial (Hollister-Stier). The total synthesis time was 45 min and [^{11}C]MeNTI was produced in good activity yield (49 ± 8 mCi), molar activity (3926 ± 326 Ci/mmol) and radiochemical purity (97 ± 2%), n=3. Quality control analysis was performed in accordance with the US Pharmacopeia, Ch. <823>,[27,28] and confirmed that doses produced using this method are suitable for human use (Table 3). Radiochemical purity and pH of batches were also re-analyzed 1 h post-EOS (end-of-

synthesis), confirming the product was stable and allowing us to assign a 1 h expiration time to doses of [^{11}C]MeNTI.

Table 3: QC data for the process verification batches of [^{11}C]MeNTI ([^{11}C]**2**).

Pre-Release QC test	Release Criteria	Batch 1	Batch 2	Batch 3
Radiochemical Purity	≥ 95%	95.4	96.3	98.7
Radioactive Concentration	≥25 mCi/10 mL batch	54.8	53.0	40.2
MeNTI Concentration	Report Result	0.66 μg/mL	0.56 μg/mL	0.41 μg/mL
Molar Activity	≥ 1500 Ci/mmol	3553	4070	4155
pH	4.5-7.5	5.0	5.0	5.0
Visual Inspection	Clear, colorless, no precipitate.	Pass	Pass	Pass
Radiochemical Identity	RRT: 0.9-1.1	1.005	0.997	1.024
Radionuclide Identity	18.4 min-22.4 min	19.9	19.6	19.8
Filter membrane Integrity test	≥ 44 psi	47	52	49
Bacterial Endotoxin test (initiated prior to release)	< 17.5 EU/mL	< 2.00	< 2.00	< 2.00
Residual Solvent Analysis	Acetone ≤ 5000 μg/mL MeCN ≤ 410 μg/mL DMF ≤ 880 μg/mL Total ≤ 10,000 μg/mL	Acetone: 9.0 μg/mL MeCN: 2.6 μg/mL DMF: nd Total: 11.6 μg/mL	Acetone: 10 μg/mL MeCN: 14 μg/mL DMF: nd Total: 24.0 μg/mL	Acetone: 11.5 μg/mL MeCN: 5.3 μg/mL DMF: nd Total: 16.8 μg/mL
Sterility	Sterile	Sterile	Sterile	Sterile

nd = not detected

4. Conclusions

In summary, a new method for the radiosynthesis of [^{11}C]MeNTI has been developed. The synthesis utilizes an easily removed MOM protecting group and straightforward chemistry, providing the product in good radiochemical yield, molar activity and purity. The process has been fully automated using a commercially available radiosynthesis module. [^{11}C]MeNTI remains the radiotracer of choice for PET imaging of delta opioid receptors. As such, the straightforward

synthesis method described in this paper could facilitate use of [^{11}C]MeNTI PET to provide a better understanding of the role DORs have in health and neurological disorders, and assist in the development of novel DOR-targeted therapeutics.

Acknowledgements

The University of Michigan, Department of Radiology is duly acknowledged for financial assistance for this work.

Conflict of Interest

The authors do not report any conflict of interest.

References

[1] Traynor J. μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology. *Drug Alcohol Depend*, 2012;121(3): 173–180.

[2] Martin WR. Pharmacology of opioids. *Pharmacol Rev*, 1983;35(4):283–323.

[3] Wilson N, Kariisa M, Seth P, Smith IV H, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020;69:290-297.

[4] Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology 2018;43:2514–2520.

[5] Yang P-P, Yeh T-K, Loh HH, Law PY, Wang Y, Tao PL. Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice. *Eur J Pharmacol*, 2019;852:265–273.

[6] Benyhe S, Zádor F, Ötvös F. Biochemistry of opioid (morphine) receptors: binding, structure and molecular modelling. *Acta Biologica Szegediensis*. 2015;59(Suppl.1):17-37.

[7] Cumming P, Marton J, Lilius TO, Olberg DE, Rominger A. A Survey of molecular imaging of opioid receptors. *Molecules*, 2019;24(22):4190.

[8] Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. *Brain*, 2008;131(5):1171–1196.

[9] Lever JR. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. *Curr Pharm Des*, 2007;13(1):33–49.

[10] Kaur T, Wiesner N, Kilbourn MR, Scott PJH. Classics in neuroimaging: shedding light on opioid receptors with PET imaging. *ACS Chem Neurosci*. 2020;11: 2906-2914.

[11] Dannals RF, Ravert HT, Frost JJ, Wilson AA, Burns HD, and Wagner Jr. HN. Radiosynthesis of an opiate receptor binding radiotracer: [^{11}C]carfentanil. *Int J Appl Radiat Isot* 1985;36(4):303–306.

[12] Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta J-K, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJH, Shao X. An updated synthesis of [^{11}C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor. *J Labelled Comp Radiopharm*, 2017;60(8):375–380.

[13] Naganawa M, Zheng M-Q, Nabulsi N, Tomasi G, Henry S, Lin S-F, Ropchan J, Labaree D, Tauscher J, Neumeister A, Carson RE, Huang Y. Kinetic modeling of ^{11}C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. *J Cereb Blood Flow Metab* 2015;34:1818–1825.

[14] Yang L, Brooks AF, Makaravage KJ, Zhang H, Sanford MS, Scott PJH, Shao X.: Radiosynthesis of [^{11}C]LY2795050 for preclinical and clinical pet imaging using Cu(II)-mediated cyanation. *ACS Med Chem Lett* 2018;9:1274-1279.

[15] Lohith TG, Zoghbi SS, Morse CL, Ferraris Araneta MD, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M. Retest imaging of [^{11}C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. *NeuroImage* 2014;87:89–95.

[16] Shao X, Fawaz MV, Stewart MN, Sherman P, Quesada C, Kilbourn MR, Saccone P, Crossno J, Winger G, Woods JH, Scott PJH. Validation of NOP-induced analgesia in rhesus macaques via microPET Imaging with [^{11}C]NOP-1A. *Abstracts of PET Chemistry UK, Newcastle upon Tyne, UK*, 2013.

[17] Usai EM, Manca I, Pettinau F, Mastino A, Pittau B. Chemical characterization and in vitro metabolism of a novel class of delta opioid receptor agonists, analogs of SNC-80. *ChemistrySelect*, 2019;4(7):2109–2115.

[18] Bidlack JM. Detection and function of opioid receptors on cells from the immune system. *Clin Diagn Lab Immunol*, 2000;7(5):719-723.

[19] Lever JR, Kinter CM, Ravert HT, Musachio JL, Mathews WB, Dannals RF. Synthesis of N_1'-([^{11}C]methyl)naltrindole ([^{11}C]MeNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. *J. Label Compd Radiopharm*, 1995;36(2):137–145.

[20] Portoghese PS, Sultana M, Takemori AE. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept. *J Med Chem*, 1990;33(6):1714–1720.

[21] Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL, Mathews WB, Dannals RF, Frost JJ. Imaging of delta opioid receptors in human brain by N_1'-([^{11}C]methyl)naltrindole and PET. *Synapse*, 1996;24(1):19–28.

[22] Lever JR, Scheffel U, Kinter CM, Ravert HT, Dannals RF, Wagner HN, Frost JJ. In vivo binding of N_1'-([11C]methyl)naltrindole to delta-opioid receptors in mouse brain. *Eur J Pharmacol*, 1992;216(3):459–460.

[23] Villemagne PSR, Dannals RF, Ravert HT, Frost JJ. PET imaging of human cardiac opioid receptors. *Eur J Nucl Med Mol Imaging*. 2002;29(10):1385-1388.

[24] Madar I, Bencherif B, Lever J, Heitmiller RF, Yang SC, Brock M, Brahmer J, Ravert H, Dannals R, Frost JJ. Imaging δ and μ-opioid receptors by PET in lung carcinoma patients. J Nucl Med 2007;48(2):207–213.

[25] Liang SH, Collier TL, Rotstein BH, Lewis R, Steck M, Vasdev N. Rapid microfluidic flow hydrogenation for reduction or deprotection of ^{18}F-labeled compounds. *Chem Commun*, 2013;49(78):8755-8757.

[26] Mossine AV, Brooks AF, Henderson BD, Hockley BG, Frey KA, Scott PJH. An updated radiosynthesis of [^{18}F]AV1451 for tau PET imaging. *EJNMMI Radiopharm Chem*, 2017;2(1):7.

[27] Shao X, Hoareau R, Runkle AC, Tluczek LJM, Hockley BG, Henderson BD, Scott PJH. Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [^{11}C]-labeled radiopharmaceuticals using a Tracerlab $FX_{C\text{-}Pro}$. *J. Label Compd Radiopharm*. 2011;54(14):819–838.

[28] USP <823> Positron emission tomography drugs for compounding, investigational, and research uses radiopharmaceuticals for positron emission tomography, in USP 43-NF 38, The United States Pharmacopeia Convention, Rockville, 2020.

[29] Duval A, Lever JR. Fischer indole synthesis in water : simple, efficient preparation of naltrindole , naltriben and analogs. *Green Chem*, 2010;12(2):304–309.

[30] Shao X, Fawaz MV, Jang K, Scott PJH. Ethanolic carbon-11 chemistry: The introduction of green radiochemistry. *Appl Radiat Isot* 2014;89:125-129.